Skip to main content

Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE

Research Question:
Does the drug dupilumab help patients with alopecia areata?

Basic Study Information

Alopecia Areata is patchy baldness on the scalp. This trial will enroll patients with moderate to severe alopecia areata (affecting more than 50% of the scalp) at the time of screening. Potential participants must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy. Potential participants will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).

Location: UR Dermatology at College Town
Study Reference #: STUDY00007640

Lead Researcher (Principal Investigator)

Lead Researcher:  Mary Gail Mercurio

Study Contact Information

Study Coordinator: Alicia Papalia
Phone: (585) 273-4195

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search